CytomX Therapeutics Inc (CTMX)
4.72
+0.23
(+5.14%)
USD |
NASDAQ |
May 03, 10:53
CytomX Therapeutics Enterprise Value: 129.50M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 129.50M |
| May 01, 2024 | 172.90M |
| April 30, 2024 | -64.12M |
| April 29, 2024 | -65.48M |
| April 26, 2024 | -66.83M |
| April 25, 2024 | -66.15M |
| April 24, 2024 | -64.12M |
| April 23, 2024 | -60.74M |
| April 22, 2024 | -61.41M |
| April 19, 2024 | -61.41M |
| April 18, 2024 | -57.35M |
| April 17, 2024 | -55.32M |
| April 16, 2024 | -48.55M |
| April 15, 2024 | -41.10M |
| April 12, 2024 | -28.91M |
| April 11, 2024 | -28.91M |
| April 10, 2024 | -32.29M |
| April 09, 2024 | -37.03M |
| April 08, 2024 | -35.00M |
| April 05, 2024 | -35.00M |
| April 04, 2024 | -35.00M |
| April 03, 2024 | -28.91M |
| April 02, 2024 | -29.58M |
| April 01, 2024 | -28.91M |
| March 28, 2024 | -26.88M |
| Date | Value |
|---|---|
| March 27, 2024 | -26.20M |
| March 26, 2024 | -31.62M |
| March 25, 2024 | -29.58M |
| March 22, 2024 | -31.62M |
| March 21, 2024 | -22.81M |
| March 20, 2024 | -20.78M |
| March 19, 2024 | -26.88M |
| March 18, 2024 | -37.71M |
| March 15, 2024 | -34.33M |
| March 14, 2024 | -35.00M |
| March 13, 2024 | -32.29M |
| March 12, 2024 | -28.91M |
| March 11, 2024 | -4.528M |
| March 08, 2024 | -5.205M |
| March 07, 2024 | -1.141M |
| March 06, 2024 | 8.340M |
| March 05, 2024 | 9.694M |
| March 04, 2024 | 11.05M |
| March 01, 2024 | 4.954M |
| February 29, 2024 | -8.591M |
| February 28, 2024 | -3.540M |
| February 27, 2024 | -23.06M |
| February 26, 2024 | -63.45M |
| February 23, 2024 | -73.54M |
| February 22, 2024 | -74.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-162.47M
Minimum
May 09 2022
424.39M
Maximum
May 12 2020
2.657M
Average
-16.82M
Median
Jan 17 2023
Enterprise Value Benchmarks
| Ocular Therapeutix Inc | 750.82M |
| Bristol-Myers Squibb Co | 134.65B |
| ACADIA Pharmaceuticals Inc | 2.374B |
| Cytokinetics Inc | 6.634B |
| Calidi Biotherapeutics Inc | 8.061M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.837M |
| Revenue (Quarterly) | 26.61M |
| Total Expenses (Quarterly) | 27.21M |
| EPS Diluted (Quarterly) | 0.01 |
| Profit Margin (Quarterly) | 3.15% |
| Earnings Yield | -0.42% |
| Normalized Earnings Yield | -0.4237 |